- Kurt thought there was a 50% chance all GLP-1 compounding would end in the next 6 months (both 503A and 503B) - Did not mention direct communication from the FDA telling them to stop compounding GLP-1s - ProRx felt it was time to stop due to the end of the shortage in March 2025, and did not feel influenced by the April 1 FDA statement - Kurt thinks 503B production of GLP-1s are underreported and much larger than thought - 503As can't take care of the compounded GLP-1 market at their current capacity - We both have concerns about patient access without compounded GLP-1s and worry it will send more patients to the grey market for RUO injections that don't have the same level of sterility and regulation To view or add a comment, sign in Yesterday the FDA proposed removing GLP-1s from the 503B bulk list, and I spoke to Kurt Lunkwitz from ProRx to talk about changes to GLP-1 compounding
In head-to-head and trial data, tirzepatide has generally produced greater average weight loss, though the best choice depends on tolerability, cost, and medical history
He explains how untapped emotions and stress can cause physical symptoms that resemble a heart attack, and why its critical to give in to your feelings and cry
Peptides step in to support collagen, and soybean oil helps hydrate, soothe, and decrease any redness that may come from the retinoid, she adds
holds a Career Award at the Scientific Interface from Burroughs Welcome Fund
